Protalix BioTherapeutics, Inc.
PLX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $136,358 | $120,173 | $66,407 | $36,711 |
| - Cash | $19,760 | $23,634 | $17,111 | $38,985 |
| + Debt | $5,526 | $27,690 | $33,474 | $33,470 |
| Enterprise Value | $122,124 | $124,229 | $82,770 | $31,196 |
| Revenue | $53,399 | $65,494 | $47,638 | $38,350 |
| % Growth | -18.5% | 37.5% | 24.2% | – |
| Gross Profit | $29,080 | $42,512 | $28,046 | $22,001 |
| % Margin | 54.5% | 64.9% | 58.9% | 57.4% |
| EBITDA | $6,520 | $12,937 | -$10,782 | -$18,943 |
| % Margin | 12.2% | 19.8% | -22.6% | -49.4% |
| Net Income | $2,932 | $8,312 | -$14,927 | -$27,582 |
| % Margin | 5.5% | 12.7% | -31.3% | -71.9% |
| EPS Diluted | 0.037 | 0.1 | -0.31 | -0.62 |
| % Growth | -63.4% | 132.3% | 50% | – |
| Operating Cash Flow | $8,674 | -$1,318 | -$25,000 | -$10,285 |
| Capital Expenditures | -$1,282 | -$1,149 | -$628 | -$1,459 |
| Free Cash Flow | $7,392 | -$2,467 | -$25,628 | -$11,744 |